Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish National Registry of Urinary Bladder Cancer

Research output: Contribution to journalArticle

Standard

Gender-related differences in urothelial carcinoma of the bladder : a population-based study from the Swedish National Registry of Urinary Bladder Cancer. / Thorstenson, Andreas; Hagberg, Oskar; Ljungberg, Börje; Liedberg, Fredrik; Jancke, Georg; Holmäng, Sten; Malmström, Per-Uno; Hosseini, Abolfazl; Jahnson, Staffan.

In: Scandinavian Journal of Urology, Vol. 50, No. 4, 2016, p. 292-297.

Research output: Contribution to journalArticle

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - Gender-related differences in urothelial carcinoma of the bladder

T2 - Scandinavian Journal of Urology

AU - Thorstenson, Andreas

AU - Hagberg, Oskar

AU - Ljungberg, Börje

AU - Liedberg, Fredrik

AU - Jancke, Georg

AU - Holmäng, Sten

AU - Malmström, Per-Uno

AU - Hosseini, Abolfazl

AU - Jahnson, Staffan

PY - 2016

Y1 - 2016

N2 - OBJECTIVE: The aim of this investigation was to describe tumour characteristics, treatments and survival in patients with urinary bladder cancer (UBC) in a national population-based cohort, with special reference to gender-related differences.MATERIAL AND METHODS: All primary UBC patients with urothelial pathology reported to the Swedish National Registry of Urinary Bladder Cancer (SNRUBC) from 1997 to 2011 were included in the study. Groups were compared regarding tumour, node, metastasis classification, primary treatment and survival.RESULTS: In total, 30,310 patients (74.9% male, 25.1% female) with UBC were analysed. A larger proportion of women than men had stage T2-T4 (p < 0.001), and women also had more G1 tumours (p < 0.001). However, compared to women, a larger proportion of men with carcinoma in situ or T1G3 received intravesical treatment with bacillus Calmette-Guérin or intravesical chemotherapy, and a larger proportion of men with stage T2-T4 underwent radical cystectomy (38% men vs 33% women, p < 0.0001). The cancer-specific survival at 5 years was 77% for men and 72% for women (p < 0.001), and the relative survival at 5 years was 72% for men and 69% for women (p < 0.001).CONCLUSIONS: In this population-based cohort comprising virtually all patients diagnosed with UBC in Sweden between 1997 and 2011, female gender was associated with inferior cancer-specific and relative survival. Although women had a higher rate of aggressive tumours, a smaller proportion of women than men received optimal treatment.

AB - OBJECTIVE: The aim of this investigation was to describe tumour characteristics, treatments and survival in patients with urinary bladder cancer (UBC) in a national population-based cohort, with special reference to gender-related differences.MATERIAL AND METHODS: All primary UBC patients with urothelial pathology reported to the Swedish National Registry of Urinary Bladder Cancer (SNRUBC) from 1997 to 2011 were included in the study. Groups were compared regarding tumour, node, metastasis classification, primary treatment and survival.RESULTS: In total, 30,310 patients (74.9% male, 25.1% female) with UBC were analysed. A larger proportion of women than men had stage T2-T4 (p < 0.001), and women also had more G1 tumours (p < 0.001). However, compared to women, a larger proportion of men with carcinoma in situ or T1G3 received intravesical treatment with bacillus Calmette-Guérin or intravesical chemotherapy, and a larger proportion of men with stage T2-T4 underwent radical cystectomy (38% men vs 33% women, p < 0.0001). The cancer-specific survival at 5 years was 77% for men and 72% for women (p < 0.001), and the relative survival at 5 years was 72% for men and 69% for women (p < 0.001).CONCLUSIONS: In this population-based cohort comprising virtually all patients diagnosed with UBC in Sweden between 1997 and 2011, female gender was associated with inferior cancer-specific and relative survival. Although women had a higher rate of aggressive tumours, a smaller proportion of women than men received optimal treatment.

U2 - 10.3109/21681805.2016.1158207

DO - 10.3109/21681805.2016.1158207

M3 - Article

VL - 50

SP - 292

EP - 297

JO - Scandinavian Journal of Urology

JF - Scandinavian Journal of Urology

SN - 2168-1813

IS - 4

ER -